leflunomide has been researched along with Giant Cell Arteritis in 12 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Giant Cell Arteritis: A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness of leflunomide as a steroid-sparing agent among Indian patients with giant cell arteritis (GCA) and to assess the changes of "halo sign" within affected arteries, detected ultrasonographically, after remission." | 8.12 | Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study. ( Das, S; Datta, A; Ghosal, A; Goswami, RP; Sarkar, S; Sinha, D, 2022) |
| " This report aims to assess the effectiveness and safety of leflunomide (LEF) in Takayasu arteritis (TA) and giant cell arteritis (GCA)." | 5.41 | Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies. ( Brugarolas, E; Estrada, P; LLop, D; Maymó-Paituvi, P; Narváez, J; Nolla, JM; Palacios-Olid, J; Vidal-Montal, P, 2023) |
| " Results of in-vitro studies on Janus kinase (JAK)/signal transducers and activators of transcription and mammalian target of rapamycin (mTOR) pathways, comparative studies with leflunomide as an induction therapy, and a long-term follow-up study with tocilizumab may contribute to the management of Takayasu arteritis." | 5.12 | Aortitis: an update. ( Erdogan, M, 2021) |
| "To evaluate the effectiveness of leflunomide as a steroid-sparing agent among Indian patients with giant cell arteritis (GCA) and to assess the changes of "halo sign" within affected arteries, detected ultrasonographically, after remission." | 4.12 | Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study. ( Das, S; Datta, A; Ghosal, A; Goswami, RP; Sarkar, S; Sinha, D, 2022) |
| "Treatment with leflunomide or low doses of glucocorticoids were not associated with severe course in our cohort." | 2.82 | COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia. ( Hočevar, A; Ješe, R; Kramarič, J; Rotar, Ž; Tomšič, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, S | 1 |
| Goswami, RP | 1 |
| Sinha, D | 1 |
| Ghosal, A | 1 |
| Datta, A | 1 |
| Sarkar, S | 1 |
| Kramarič, J | 1 |
| Ješe, R | 2 |
| Tomšič, M | 2 |
| Rotar, Ž | 2 |
| Hočevar, A | 2 |
| Narváez, J | 1 |
| Estrada, P | 1 |
| LLop, D | 1 |
| Vidal-Montal, P | 1 |
| Brugarolas, E | 1 |
| Maymó-Paituvi, P | 1 |
| Palacios-Olid, J | 1 |
| Nolla, JM | 1 |
| Sebastian, A | 2 |
| Kayani, A | 2 |
| Dasgupta, B | 3 |
| Erdogan, M | 1 |
| Tomelleri, A | 1 |
| Coath, F | 1 |
| Prieto-Pena, D | 1 |
| Mo, J | 1 |
| Tengesdal, S | 1 |
| Diamantopoulos, AP | 2 |
| Myklebust, G | 2 |
| Samson, M | 1 |
| Greigert, H | 1 |
| Ghesquière, T | 1 |
| Bonnotte, B | 1 |
| Hetland, H | 1 |
| Adizie, T | 1 |
| Christidis, D | 1 |
| Dharmapaliah, C | 1 |
| Borg, F | 1 |
| Unizony, S | 1 |
| Stone, JH | 1 |
| Stone, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Randomized Placebo Controlled Treatment Study of Leflunomide in Polymyalgia Rheumatica[NCT03576794] | Phase 3 | 94 participants (Anticipated) | Interventional | 2019-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for leflunomide and Giant Cell Arteritis
| Article | Year |
|---|---|
COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.
Topics: Cardiovascular Diseases; COVID-19; Giant Cell Arteritis; Glucocorticoids; Humans; Hypertension; Lefl | 2022 |
Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
Topics: Antirheumatic Agents; Cohort Studies; Giant Cell Arteritis; Glucocorticoids; Humans; Leflunomide; Me | 2023 |
Aortitis: an update.
Topics: Antibodies, Monoclonal, Humanized; Aorta; Aortitis; Female; Follow-Up Studies; Giant Cell Arteritis; | 2021 |
[Treatment of giant cell arteritis].
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Azat | 2019 |
New treatment strategies in large-vessel vasculitis.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Arteritis; Giant Cell Art | 2013 |
7 other studies available for leflunomide and Giant Cell Arteritis
| Article | Year |
|---|---|
Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study.
Topics: Follow-Up Studies; Giant Cell Arteritis; Humans; Leflunomide; Prednisolone; Recurrence; Steroids | 2022 |
Excellent Response to Leflunomide in a Case of Large-Vessel Giant Cell Arteritis Demonstrated Simultaneously by Clinical, Laboratory, Ultrasound, and Positron Emission Tomography/Computed Tomography Parameters.
Topics: Aged; Female; Fluorodeoxyglucose F18; Giant Cell Arteritis; Humans; Laboratories; Leflunomide; Posit | 2021 |
Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis: A Single-Center, 10-Year Experience.
Topics: Giant Cell Arteritis; Humans; Leflunomide; Takayasu Arteritis | 2022 |
Does leflunomide have a role in giant cell arteritis? An open-label study.
Topics: Aged; Drug Therapy, Combination; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Immunosuppre | 2019 |
Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival.
Topics: Aged; Antirheumatic Agents; Dose-Response Relationship, Drug; Drug Monitoring; Female; Giant Cell Ar | 2019 |
Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.
Topics: Adrenal Cortex Hormones; Aged; Female; Giant Cell Arteritis; Giant Cells; Humans; Isoxazoles; Leflun | 2013 |
Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Case-Control Studies; Female; Giant Cell Arteritis; H | 2012 |